Bordetella holmesii is a recently identified gram-negative bacterial species associated with bacteremia, endocarditis, and respiratory illness, mainly in immunocompromised patients. From isolates submitted to the Centers for Disease Control and Prevention from 1983 through 2000 for further identification, we identified 30 patients with B. holmesii bacteremia. Of the 26 patients for whom data were available, 22 (85%) were anatomically or functionally asplenic. In 25 (96%) of the 26 patients, B. holmesii was the only organism isolated from blood samples, and 14 patients (54%) had B. holmesii recovered from у2 blood cultures. The clinical course of the infection was generally characterized by a nonspecific febrile illness. Twenty-one patients (81%) were treated with various antimicrobial agents, and 20 (77%) were admitted to the hospital. There were no deaths. Our findings support evidence that B. holmesii may be a true pathogen associated with bacteremia among asplenic patients.
Since 1995, several published articles have reported potential clinical manifestations of B. holmesii infection. However, these case reports and small case studies either provided limited clinical and exposure history [1] , contained a small number of patients [2] [3] [4] [5] [6] [7] , or included only patients who had cough and from whom the organism was isolated from the nasopharynx [8] . To obtain a more detailed picture of the clinical features and epidemiological significance of this newly identified bacterial species, we reviewed the medical records of patients who had clinical isolates sent to the CDC that were subsequently identified as B. holmesii.
METHODS
We defined a case patient as a resident of the United States from whom B. holmesii was isolated from a normally sterile site. Case finding was performed from unidentified bacterial isolates that had been sent to the CDC's Special Bacteriology Reference Laboratory (SBRL) from 1983 through 2000 for identification and typing, including the 15 strains included in the initial description of this species [1] . We also included in our case finding isolates provisionally identified as B. hol-mesii by referring institutions and submitted to the SBRL for confirmation.
In collaboration with the state health department and the infection-control practitioner from the submitting institution, we obtained and reviewed the medical records for each identified patient. Variables collected included patient demographic characteristics, clinical signs and symptoms, laboratory results, treatment, and outcome. We collected data on a standardized form and analyzed these data using SAS software, version 8.2 (SAS Institute). We described categorical variables as proportions and compared them using the Mantel-Haenszel x 2 or Fisher's exact test. We described continuous variables with medians and ranges.
Microbiological confirmation of the B. holmesii strains in this study was initially performed in the months just after receipt of each isolate at the CDC using the methods of the CDC's SBRL [9] . The 15 strains described by Weyant et al. [1] were also confirmed to be B. holmesii by whole chromosomal DNA-DNA hybridization before 1995. In 2003, 16S rDNA sequence analysis was performed on available isolates for which associated epidemiological data were obtained. The methods used for PCR amplification of rDNA, its sequencing, and analysis of data were described previously [10] . All nucleotide positions not identical with the 22 dominant isolates' identities were reviewed at the chromatogram level for all strains sequenced in the study.
Each available isolate for which associated epidemiological data were obtained was also tested for antimicrobial susceptibility by the broth microdilution method, in accordance with the NCCLS guidelines [11] . Antimicrobial agent powders were obtained from Sigma, Eli Lilly & Company, Johnson & Johnson, USP, Zeneca, Bayer, Bristol-Myers Squibb, and Rhone-PoulencRorer. Inocula were prepared by direct colony suspension from a 5% sheep blood agar plate incubated at 35ЊC for 48 h in ambient air. The isolates were tested using in-house prepared plates containing antimicrobial agents and cation-adjusted Mueller-Hinton broth (Difco brand; BD) with 4% lysed horse blood. Plates were incubated in ambient air at 35ЊC. MICs were determined at 20-24 h and again at 48 h. Growth end points were significantly more discernible at 48 h; therefore, the data from the reading at 48 h are shown. Quality-control strains included Streptococcus pneumoniae ATCC 49619 and Enterococcus faecalis ATCC 29212.
RESULTS
Thirty patients met our case definition, including 12 of 15 cases included in the initial description of this species by Weyant et al. [1] . All 30 had B. holmesii isolated from blood culture specimens. Clinical and demographic data were available for 26 (87%) of the 30 patients identified. We were able to obtain data from the medical records for 24 patients, and for the remaining 2, we obtained information from published case reports [2, 3] . Demographic information for 9 patients was briefly described previously [1] .
Demographic characteristics. Of the 26 patients, 14 (54%) were male. The median age was 20.5 years (range, 10 months to 80 years), and 22 (85%) patients were aged !40 years. Thirteen patients (50%) were African American, and 12 (46%) were white. There was a fall-winter predominance for the date of illness-onset associated with B. holmesii infections, with 19 cases (73%) occurring during the period of October through March and 7 cases occurring during the remaining half of the year ( ). Isolates were submitted from 16 different states, with P ! .01 no geographic clustering ( figure 1) . Although the number of B. holmesii isolates submitted to the CDC increased in 1995 after publication of the first article describing this new bacterial species [1] , there was no significant change in the number of isolates received per year (figure 2).
Predisposing conditions. Twenty-two (85%) of the 26 patients were functionally or anatomically asplenic at the time of infection. Reasons for asplenia included sickle cell disease ( ), trauma ( ), splenectomy for lymphoma treatn p 10 n p 4 ment or staging ( ), idiopathic thrombocytopenic purpura n p 3 ( ), hereditary spherocytosis ( ), thrombocytopenia n p 2 n p 1 ( ), and unknown reasons ( ). The 4 patients who n p 1 n p 1 were not asplenic included an 80-year-old patient receiving long-term steroid therapy for rheumatoid arthritis, a 43-yearold renal transplant recipient, a 29-year-old patient with AIDS, and an infant with no identified underlying medical conditions (table 1) .
Clinical presentation and course. In general, the clinical course of B. holmesii-infected patients was characterized by a mild febrile illness. The median temperature at presentation was 38.3ЊC (range, 36.1ЊC-40.0Њ C), and 19 patients (73%) had a temperature of 138.0ЊC. Thirteen patients (50%) reported having a headache. Other common symptoms included chills, vomiting, and cough (table 2) .
Among the 22 patients for whom basic hospital admission laboratory data were available, the median WBC count was 13,700 cells/mm 3 (range, 5700-24,900 cells/mm 3 ). The median hematocrit was 35% (range, 18%-46%), and the median platelet count was 332,000 cells/mm 3 (range 99,000-497,000 cells/ mm 3 ). B. holmesii was isolated from cultures of blood samples obtained !24 h after presentation for 25 patients (96%); the remaining patient's initial blood sample was obtained 2 days after presentation. Although 12 patients (46%) had only 1 blood culture positive for B. holmesii, 14 (54%) patients had B. holmesii isolated from у2 cultures of blood samples obtained at different times during the same hospitalization or outpatient visit. For 25 (96%) of the 26 patients B. holmesii was the only organism isolated from blood culture. The remaining patient had a mixed culture of B. holmesii and a streptococcal species.
Eleven patients (42%) were given a primary discharge diagnosis of bacteremia. Primary discharge diagnoses for the remaining patients were viral syndrome (4 patients), endocarditis (2 patients), pneumonia (2 patients), sickle cell crisis (2 patients), septic arthritis (1 patient), pyelonephritis (1 patient), and cellulitis (1 patient). Two patients (8%) had microbiological evidence of other potential causes of febrile illness. One was an 80-year-old patient receiving long-term steroid therapy for rheumatoid arthritis who presented with weakness and dehydration and who had a urine culture positive for Escherichia coli, and the other was a 21-year-old asplenic patient with presenting symptoms of headache, neck pain, and fever who had a urethral swab positive for Chlamydia trachomatis. Both patients were given a discharge diagnosis of bacteremia.
Treatment and outcome. Twenty patients (77%) were admitted to the hospital. The median length of stay was 7 days (range, 2-66 days). Twenty-one (81%) of 26 patients were treated with antimicrobial agents, including aminoglycosides, macrolides, cephalosporins, penicillin, metronidazole, doxycycline, and vancomycin. There were no deaths associated with B. holmesii bacteremia in this cohort. One patient required intensive care unit (ICU) admission. This 35-year-old man with a history of Hodgkin disease and splenectomy developed aortic valve endocarditis and valvular abscess, and he required multiple surgical procedures and a prolonged hospitalization.
16S rDNA sequence analysis of B. holmesii strains. Of the 26 isolates, 24 were tested to determine 16S rDNA sequence. These 16S rDNA sequences were compared with each other and with the sequences of 7 other Bordetella species and Alcaligenes defragrans from GenBank. The resulting phylogenetic tree (figure 3) demonstrates the close relationship between the different B. holmesii strains and the relationship of B. holmesii to other members of Bordetella genus. The B. holmesii strains displayed very little 16S rDNA sequence heterogeneity, with 1 or 0 bases differing from the 1525 base pairs in the type strain (ATCC51541, CDC F5101). The lowest percentage similarity of 16S rDNA sequences of any 2 of the 24 B. holmesii isolates was 99.93%, which exceeded the maximum percentage similarity (99.52%) between type strains of the most closely related pair of Bordetella species, Bordetella bronchiseptica and Bordetella parapertussis. This close molecular relationship between strains strongly suggests that all 24 B. holmesii isolates belong to the same species.
Antimicrobial susceptibility. Of the 26 isolates, 25 were tested for antimicrobial susceptibility. The susceptibility patterns of the 25 isolates were similar (table 3) . There are no established interpretive breakpoints for this organism, but, in general, the MICs of the b-lactam drugs, including the ceph- alosporins, were high relative to susceptibility breakpoints of several common aerobic gram-negative bacterial pathogens [11] . For example, for 16 isolates (64%), the MIC of ampicillin was у4 mg/mL, and for 21 isolates (84%), the MIC of cefotaxime was 18 mg/mL. In contrast, the MICs of the carbapenems, fluoroquinolones, and trimethoprim-sulfamethoxazole were low. For 8 isolates (32%), the MIC of imipenem was 0.5 mg/mL, and it was 1.0 mg/mL for the remaining 17 (68%). For all 25 isolates, the MIC of ciprofloxacin was р0.5 mg/mL, and for 24 isolates (96%), the MIC of levofloxacin was р0.25 mg/ mL. For 22 isolates (88%), the MIC of trimethoprim-sulfamethoxazole was р0.5/9.5 mg/mL. An MIC of erythromycin of р2 mg/mL was noted for 22 isolates (88%). Azithromycin and clarithromycin were not evaluated.
DISCUSSION
B. holmesii was first isolated in 1983, and the initial manuscript naming the new bacterial species was published in 1995. It has been associated with bacteremia, endocarditis, and respiratory illness in humans [1] [2] [3] [4] [5] [6] [7] [8] . As with other previously unrecognized bacterial pathogens, a clear description of the associated clinical syndrome and epidemiology of B. holmesii should emerge slowly through the publication of case reports and case series. Clinically oriented B. holmesii literature is, to date, limited, because it is either based on small numbers of affected patients or on isolates recovered from nonsterile sites. For the clinician, determining the significance of a clinical isolate of B. holmesii with this paucity of information is difficult. The 26 patients with B. holmesii bacteremia described here offer the strongest argument that B. holmesii is a pathogenic organism in humans and provide an opportunity to understand its clinical spectrum. Several facts point to B. holmesii infection as the cause of the clinical illnesses described in this study. All 26 patients in this cohort had sterile site isolates positive for B. holmesii, and nearly all had у1 positive culture of a blood sample obtained within 24 h after presentation. For all but 1 of the patients studied, B. holmesii was the only organism isolated from the blood. More than one-half of these patients had у2 blood cultures positive for B. holmesii, and the samples had been obtained from separate sites during the same hospitalization or outpatient visit. Finally, only 2 patients had cultures of samples from other sites positive for a different bacterial pathogen, and neither represents a likely etiology of the associated clinical syndromes.
The most striking feature of this cohort of patients was the large proportion of patients with functional or anatomic asplenia, including a substantial number (38%) with sickle cell disease. Prior case reports and case series have documented the association of B. holmesii infection and underlying conditions, such as Hodgkin disease, chronic obstructive pulmonary disease, asplenia, and end-stage renal disease [1] [2] [3] [4] [5] [6] [7] [8] , but none have reported as large a proportion of cases in asplenic hosts as was reported for this cohort. This association may be due to immunodeficiencies in asplenic patients that increase risk for B. holmesii infection, but it may also reflect the reporting bias of clinicians who are more likely to pursue identification of a bacterial isolate recovered from an immunocompromised patient.
Most of the clinical illnesses associated with B. holmesii infections in this cohort were relatively mild. Although severe disease associated with B. holmesii has been reported [7] , in this cohort, no deaths were noted, only 1 patient required ICU care, and 6 patients were treated as outpatients. One-half of those hospitalized were discharged within 1 week, and no longterm sequelae from this infection were noted at discharge.
The ability of B. holmesii to colonize the respiratory tract has led some investigators to speculate that this organism may cause respiratory illness in humans [4, 8, 12] . Although approximately one-third of the patients in this series reported respiratory symptoms, nonrespiratory symptoms were also frequently reported, and no distinctive pattern of symptoms was noted. The most prominent clinical feature was fever with few localizing signs or symptoms. However, because cases were identified by isolates sent to the CDC-and referral of unidentified bacterial isolates or B. holmesii isolates to the CDC is not a mandatory practice-they may not represent the clinical presentation, underlying illnesses, and severity of all cases of B. holmesii infection in the United States. Although our study collected valuable information about the clinical and demographic features of patients with B. holmesii infection, we found relatively little information suggesting potential modes of transmission. In recent decades, infections with 2 pathogens (Babesia species and Capnocytophaga canimorsus) have been found primarily to affect asplenic hosts with exposure to particular animals [13] [14] [15] . Domestic animals have been proposed as a reservoir for B. holmesii in 2 case reports [2, 3] ; however, few of the records reviewed in this study contained this type of exposure information.
Similarly, there are few firm conclusions to be drawn regarding treatment of B. holmesii infection. Data on clinical outcome obtained from review of medical records suggest that B. holmesii infection is generally not severe. Most patients recovered quickly and fully, although a wide array of antimicrobial treatment strategies were employed, ranging from the use of several antimicrobial agents to no antimicrobial therapy at all. Furthermore, in vitro susceptibility data suggest that many of the chosen antimicrobial regimens were probably not active against B. holmesii. The high MICs for the b-lactams, including third-generation cephalosporins, suggest that these drugs are not optimal for the treatment of B. holmesii infection. MICs of erythromycin were higher than susceptible B. pertussis isolates, suggesting that erythromycin is less active against B. holmesii [16] . In contrast, low MICs of carbapenems and fluoroquinolones suggest that these drugs may have clinical utility. However, additional data are needed to guide the interpretation of in vitro susceptibility data for this organism and to understand when or if antimicrobial therapy is necessary.
Our study represents the largest reported study of patients with B. holmesii bacteremia, and it supports the conclusion that it is a true human pathogen. Given that B. holmesii appears generally to cause a mild illness, infection may go undiagnosed and may occur more frequently than our limited number of cases would suggest. Our data suggest that asplenia may be a risk factor for B. holmesii, but much remains to be learned about its mode of transmission, pathogenesis, and natural history. Clinicians, especially when treating asplenic or otherwise immunocompromised patients, should be aware of its capacity to cause disease and be alert to potentially new clinical manifestations of this infection.
